CND Life Sciences has secured growth funding to expand the Syn-One Test, a skin biopsy-based diagnostic that detects alpha-synuclein accumulation in peripheral nerves as a biomarker for Parkinson's disease and related synucleinopathies. Early detection of pathological changes before motor symptoms emerge extends the window for intervention and represents a shift from symptom-based diagnosis toward objective tissue-level evidence.
Key Points
- Skin biopsy identifies alpha-synuclein in peripheral nerves years before motor symptoms
- Tissue-level biomarker offers different biological window than blood or cerebrospinal fluid tests
- REM sleep behavior disorder recognized as preclinical warning sign; test applicable to asymptomatic
Longevity Analysis
The ability to detect pathological change in peripheral nerve tissue before symptomatic disease manifests represents a fundamental shift in how neurodegenerative conditions are approached. Rather than waiting for clinical signs to appear—at which point irreversible damage is already extensive—this test reveals whether the disease process has begun at the cellular level. For practitioners focused on extending healthspan, this matters because it creates a genuine opportunity to intervene when neural tissue may still be preserved, fundamentally altering the risk-benefit calculus of earlier therapeutic intervention. The recognition that REM sleep behavior disorder precedes motor symptoms by years adds another layer: identifying individuals in this presymptomatic window allows preventive strategies before structural neurological damage becomes clinically apparent.
Original published by Longevity.Technology, by Kyle Umipig.